Vericel beats Q2 revenue estimates, boosts annual outlook
VCEL•Revenue drivers
- MACI growth - Company said MACI revenue rose 23% in Q2, with double-digit growth in biopsies and implants
- Burn care products - Burn care net revenue increased 22%, with record NexoBrid quarterly revenue and 21% growth in Epicel
- Sales force and marketing - Higher operating expenses were mainly due to increased headcount and expanded marketing programs
Updated outlook
- Vericel raises 2026 total revenue guidance to $330-$340 mln from $326-$336 mln
- Company expects 2026 MACI revenue of $284-$290 mln, up from prior $282-$288 mln
- Vericel maintains 2026 gross margin guidance at about 75% and adj EBITDA margin at about 27%
Quarterly results
- US advanced therapies firm's Q2 revenue rose 22%, beating analyst expectations
- Net income reached $2.2 mln, reversing a loss from prior year
- Company raised full-year 2026 revenue guidance and authorized $200 mln share buyback
